子宫内膜癌与卵巢癌中HER2评分的分布及一致性
本研究回顾性分析94例子宫内膜癌或上皮性卵巢癌患者的105份肿瘤标本,分别采用乳腺、子宫内膜和胃的HER2评分标准进行免疫组化评分。子宫内膜癌HER2高表达比例高于卵巢癌(45.2-50% vs 20.6%,p<0.05),内部三重评分一致性强(r≥0.96),但与Caris报告评分一致性较弱(r=0.66)。
要点
- 子宫内膜癌HER2高表达比例高于上皮性卵巢癌(45.2-50% vs 20.6%,p<0.05)。
- 内部三重HER2评分一致性强(r≥0.96,p<0.001),与Caris评分一致性较弱(r=0.66)。
- 23例评分不一致中13例(56.5%)会改变治疗资格,仅12例(12.7%)有中或高ERBB2扩增。
核心结论
- 无论肿瘤类型,均有临床显著比例的患者为HER2高表达肿瘤。
- 每份样本内部HER2评分一致性强,但与Caris评分相比一致性较弱。
- 作者认为,在妇科HER2评分算法中应考虑纳入多部位检测和/或外部IHC验证。
研究设计与样本
- 回顾性数据库研究,纳入2022年11月至2025年1月期间接受Caris肿瘤检测的94例子宫内膜癌或上皮性卵巢癌患者,共105份肿瘤标本。
- 每份样本分别采用乳腺、子宫内膜和胃的HER2评分标准进行免疫组化评分(0、1+、2+、3+),ERBB2扩增和HER2 IHC评分从Caris报告中获取。
- 采用描述性统计和Fisher精确检验分析患者特征及HER2评分分布,采用矩阵相关系数评估HER2评分一致性。
主要发现
- 105份样本中,上皮性卵巢癌63份,子宫内膜癌42份。
- 子宫内膜癌患者HER2高表达比例高于上皮性卵巢癌患者(45.2-50% vs 20.6%,p<0.05)。
- 内部三重HER2评分一致性强(r≥0.96,p<0.001),但与Caris评分相比一致性较弱(r=0.66)。
- 23例HER2结果不一致中,13例(56.5%)会改变治疗资格。
- 仅12例患者(12.7%)有中或高ERBB2扩增。
临床怎么用
- 作者认为,在妇科HER2评分算法中应考虑纳入多部位检测和/或外部IHC验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although multiple HER2 scoring criteria exist, the optimal strategy to identify patients with gynecologic malignancies who may benefit from HER2-directed therapies remains unknown. The objectives of this study were to assess the distribution and concordance of HER2 scores in endometrial and ovarian cancer. METHODS: One hundred five tumor specimens from 94 patients with endometrial or epithelial ovarian cancer (EOC) who underwent Caris tumor profiling from 11/2022 to 01/2025 were identified from a retrospective database. Each sample was assigned a HER2 immunohistochemistry (IHC) score of 0, 1+, 2+, or 3+ using breast, endometrial, and gastric criteria. ERBB2 amplification and HER2 IHC scores were abstracted from Caris reports. Patient characteristics and HER2 score distributions were analyzed using descriptive statistics and Fisher's exact test. Matrix correlation coefficients were used to assess HER2 score concordance. RESULTS: A total of 105 samples underwent internal triplicate HER2 scoring - 63 EOC and 42 endometrial. A higher percentage of patients with endometrial cancer were HER2-high compared to those with EOC (45.2-50 % vs 20.6 %, p < 0.05). Internal triplicate HER2 score concordance was strong (r ≥ 0.96, p < 0.001) but weaker when compared to Caris scores (r = 0.66). Of the 23 discordant HER2 results, 13 would have changed therapy eligibility (56.5 %). Only 12 patients (12.7 %) had intermediate or high ERBB2 amplification. CONCLUSIONS: A clinically significant percentage of patients had HER2-high tumors regardless of tumor type. HER2 score concordance was strong within each sample but weaker when compared to Caris scores. Incorporating multi-site testing and/or validation of external IHC into any gynecologic HER2 scoring algorithm should be considered.
引用
- Salinaro J, Singh K, Sands N, et al. Distribution and concordance of HER2 scores in endometrial and ovarian cancer. Gynecol Oncol. 2025. PMID: 40088505. doi:10.1016/j.ygyno.2025.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。